BCRX
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX) [ST]
www.biocryst.com ↗▼ 1.61%
prev close
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Congressional Trades
4
All tracked trades
Members Trading
2
Unique members
Net Activity
+2
3 buys · 1 sells
Members Who Traded This Stock
4 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2026-07-10 | BCRXBioCryst Pharmaceuticals, Inc. - Common Stock | Buy | $1,001 - $15,000 | 46d ago | — | |
| 2025-11-13 | BCRXBioCryst Pharmaceuticals, Inc. - Common Stock | Buy | $1,001 - $15,000 | 309d ago | — | |
| 2023-10-16 | BCRXBioCryst Pharmaceuticals, Inc. - Common Stock | Buy | $1,001 - $15,000 | 1074d ago | — | |
| 2023-09-15 | BCRXBioCryst Pharmaceuticals, Inc. - Common Stock | Sell | $1,001 - $15,000 | 1101d ago | — |
2026-07-10
Gilbert Cisneros
BCRX
Amount
$1,001 - $15,000
Filed
46d ago
2025-11-13
Gilbert Cisneros
BCRX
Amount
$1,001 - $15,000
Filed
309d ago
2023-10-16
Josh Gottheimer
BCRX
Amount
$1,001 - $15,000
Filed
1074d ago
2023-09-15
Josh Gottheimer
BCRX
Amount
$1,001 - $15,000
Filed
1101d ago
Recent News
Powered by Polygon.io
4 Biotech Stocks to Watch as Potential Takeover Targets
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
Trade Timeline
Congressional activity, newest first
Gilbert Cisneros
2026-07-10 · Purchase
$1,001 - $15,000
Gilbert Cisneros
2025-11-13 · Purchase
$1,001 - $15,000
Josh Gottheimer
2023-10-16 · Purchase
$1,001 - $15,000
Josh Gottheimer
2023-09-15 · Sale
$1,001 - $15,000